問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2019-08-13 - 2021-11-01

Phase I/II

A Pilot Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Treating Lower Limb Ulcers on Patients With Diabetes Mellitus

  • Condition/Disease

    Lower Limb Ulcers With Diabetes Mellitus

  • Test Drug

    TWB-103

Participate Sites
2Sites

Terminated2Sites

2017-01-01 - 2020-06-30

Phase II

A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects with Diabetic Foot Ulcers

  • Condition/Disease

    Diabetic foot ulcers，DFUs

  • Test Drug

    ENERGI-F703 GEL

Participate Sites
7Sites

Terminated7Sites

2016-10-01 - 2024-12-31

Others

A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer.

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    MTL-CEBPA

Participate Sites
4Sites

Terminated3Sites

Suspended1Sites

2017-01-01 - 2028-12-31

Phase II

A Phase II, Dose-randomization, Open-label Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    PTS100

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2009-06-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated1Sites

Study ended4Sites

2010-04-01 - 2013-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-01-20 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2006-07-01 - 2013-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2006-10-01 - 2009-10-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-08-01 - 2012-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 283 284 285 286 287 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB